Jonathan Israel

Jonathan’s practice includes patent prosecution at the European Patent Office (EPO) on behalf of a range of clients including startups, SMEs, universities, and large corporations. Jonathan also has experience in defensive and offensive oppositions before the EPO’s Opposition Divisions and Boards of Appeal, drafting patent applications, and co-ordinating global patent prosecution strategy, as well as the preparation of invalidity opinions and freedom to operate opinions (FTOs). Prior to joining Mathys & Squire, Jonathan worked at the Technology Transfer Office of Imperial College London, managing a large patent portfolio arising from the commercialisation of university inventions.

Jonathan’s technical expertise includes subject matter relating to nucleic acid-based therapies and vaccines (including COVID mRNA vaccines), infectious disease and cancer vaccines, antibodies, protein therapies, gene therapies, gene editing, diagnostics, and microbiome therapeutics.

Jonathan is a European Patent Attorney and Chartered UK Patent Attorney. He has also successfully completed a PGCert in Intellectual Property Law with distinction at Queen Mary, University of London, and holds an Intellectual Property Litigation Certificate.

Jonathan has a master’s degree in immunology from Imperial College London. His research project was concerned with the role of the IL-33/ST2 axis in the pathogenesis of idiopathic pulmonary fibrosis. Jonathan also graduated with a first class bachelor’s degree from University College London, his studies covering a broad range of topics within the Life Sciences.

Jonathan is a fellow of the Chartered Institute of Patent Attorneys (CIPA) and member of the Institute of Professional Representatives before the European Patent Office (epi).